![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/files/styles/content_image_centered/public/matysova-tab-3.jpg?itok=zVKFRXYv)
Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/65458672-7722-4ca7-a49b-92f13c344a05/gr1_lrg.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/files/styles/content_image_floated_right/public/mapka.png?itok=SdljONMc)
Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/078ffe8f-ec2e-408f-b553-b7b3f39f4629/gr4.jpg)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy | British Journal of Cancer Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.bjc.6605929/MediaObjects/41416_2010_Article_BF6605929_Fig2_HTML.jpg)
Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy | British Journal of Cancer
![Spolehlivost markerů CEA a CA 19-9 při monitoraci výsledků léčby metastatického kolorektálního karcinomu CT vyšetřením » Linkos.cz Spolehlivost markerů CEA a CA 19-9 při monitoraci výsledků léčby metastatického kolorektálního karcinomu CT vyšetřením » Linkos.cz](http://www.linkos.cz/files/abstrakta/JOD2011/p01_03.jpg)